1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883.T
Modalis Therapeutics CorporationJP flagTokyo Stock Exchange
34.00
JPY
- -
- -
3.28BMarket Cap

Total Valuation

Modalis Therapeutics Corporation carries a market capitalization of 3.28B, placing it among publicly traded companies globally. Its enterprise value stands at 1.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.28B
Enterprise Value1.25B

Share Statistics

Modalis Therapeutics Corporation currently has 39.44M shares outstanding.

Shares Outstanding39.44M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

PE RatioN/A
PS RatioN/A
PB Ratio-4.59
P/TBV Ratio2.12
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

EV / SalesN/A
EV / EBITDAN/A
EV / EBITN/A
EV / FCF292.44

Financial Position

Modalis Therapeutics Corporation maintains a current ratio of 12.91, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.60, indicating elevated leverage, while an interest coverage ratio of -508.30 demonstrates limited ability to service its debt obligations.

Current Ratio12.91
Quick Ratio12.38
Debt / Equity14.60
Debt / EBITDA-0.08
Interest Coverage-508.30

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-100.32
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax1.21M
Effective Tax RateN/A

Stock Price Statistics

Modalis Therapeutics Corporation's stock has declined approximately -58.53659% over the past 52 weeks. The 50-day moving average sits at 48.10, while the 200-day moving average is 59.72.

Beta (5Y)N/A
52-Week Price Change-58.53659%
50-Day Moving Average48.10
200-Day Moving Average59.72
Average Volume (20 Days)N/A

Income Statement

EBITDA reached -2.16B, while operating income came in at -2.16B.

RevenueN/A
Gross ProfitN/A
Operating Income-2.16B
Pretax Income-2.14B
Net Income-2.14B
EBITDA-2.16B
EBIT-2.16B
Earnings Per Share (EPS)-63.41

Balance Sheet

Modalis Therapeutics Corporation holds 1.28B in cash and equivalents against 162.50M in total debt, resulting in a net debt position of -1.12B. Total book value stands at -515.09M, with working capital of 1.23B providing operational flexibility.

Cash & Cash Equivalents1.28B
Total Debt162.50M
Net Debt-1.12B
Equity (Book Value)-515.09M
Book Value Per Share-15.27
Working Capital1.23B

Scores

Modalis Therapeutics Corporation posts an Altman Z-Score of -0.03, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.03